Loomis, Sayles & Company’s Rhythm Pharmaceuticals RYTM Stock Holding History

Loomis, Sayles & Company’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.2M	Sell	434,102 -31,000	-7%	-$2.8M	0.06%	120
2026 Q1	$40.4M	Sell	465,102 -38,799	-8%	-$3.77M	0.05%	124
2025 Q4	$53.9M	Sell	503,901 -23,538	-4%	-$2.5M	0.07%	98
2025 Q3	$53.3M	Sell	527,439 -64,015	-11%	-$5.94M	0.06%	107
2025 Q2	$37.4M	Sell	591,454 -14,310	-2%	-$876K	0.05%	144
2025 Q1	$32.1M	Sell	605,764 -12,721	-2%	-$706K	0.05%	159
2024 Q4	$34.6M	Sell	618,485 -18,143	-3%	-$1M	0.04%	168
2024 Q3	$33.4M	Buy	+636,628	New	+$30.5M	0.04%	181

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Loomis, Sayles & Company's RYTM Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Rhythm Pharmaceuticals (RYTM) stake by 6.7% in Q2 2026, selling an estimated $2.8M and leaving 434,102 shares worth $48.2M. The position accounts for 0.06% of the portfolio, ranked #120.

Loomis, Sayles & Company first reported a position in RYTM in Q3 2024 and has held it in 8 quarters since. The position peaked at $53.9M in Q4 2025. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Loomis, Sayles & Company held 434,102 shares of Rhythm Pharmaceuticals worth $48.2M as of Q2 2026.
Loomis, Sayles & Company sold 31,000 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.8M.
Rhythm Pharmaceuticals made up 0.06% of Loomis, Sayles & Company's portfolio in Q2 2026, its #120 holding.
Loomis, Sayles & Company first reported a position in Rhythm Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Loomis, Sayles & Company's Rhythm Pharmaceuticals position peaked at $53.9M in Q4 2025.
302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.